Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Key Takeaway: Amylyx Pharmaceuticals has announced the initiation of a U.S. Expanded Access Program for adults suffering from post-bariatric hypoglycemia. This program aims to provide access to their treatment for patients who may not qualify for clinical trials. The announcement highlights the company's commitment to addressing this condition.